FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Presented at AACR 2016, New Orleans, US

Franck Brichory (1), Anna Pokorska-Bocci (1), Paolo Nuciforo (2), Stefania Rigotti (1), Nathalie Lembrez (1), GrégoireVuagniaux (1), Corinne Moulon (1), Anne Vaslin (1)

1. Debiopharm International SA, Switzerland.
2. Vall d’HebronInstitute of Oncology, Spain.